Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• Wegovy (Novo Nordisk) is an FDA‑approved, proprietary formulation of semaglutide for chronic weight management with standardized dosing, prefilled pens, and results/safety data from large clinical trials.
• “Compounded semaglutide” is a product made by a pharmacy from bulk API or from repackaged vials/pens. It is not FDA‑approved as a finished drug product and can vary in concentration, purity, sterility, stability and labeling. That creates potential safety, legal and efficacy differences.

Key differences (what matters to you)

• Regulatory approval and evidence
  • Wegovy: reviewed and approved by the FDA for weight loss after controlled clinical trials (so efficacy, dosing schedule, and safety profile are established in that population).
  • Compounded: not FDA‑approved. No required clinical testing of that specific product or delivery method.
• Quality control and consistency
  • Wegovy: manufactured under strict GMP controls; each lot tested by the manufacturer.
  • Compounded: quality depends on the pharmacy’s practices. There is more variability in potency, impurities and sterility risk unless the pharmacy is an accredited, regulated outsourcing facility.
• Sterility and infection risk
  • Wegovy pens are sterile single‑use devices made for SC injection.
  • Compounded products (especially prefilled syringes or multi‑use vials) can carry a higher risk for contamination if not prepared in an appropriate cleanroom (USP <797>/<800>) or by an FDA‑registered 503B outsourcing facility.
• Dosing, concentration and delivery device
  • Wegovy comes in specified pen strengths and a standardized titration schedule (up to 2.4 mg weekly).
  • Compounded products may come in different concentrations or require drawing up doses, increasing chances of dosing errors.
• Safety monitoring and adverse events
  • Wegovy’s adverse‑event profile is documented in trials and the label gives guidance on risks (thyroid C‑cell tumor risk in animals, pancreatitis, gallbladder disease, etc.).
  • Compounded semaglutide will have similar pharmacologic side effects, but additional safety concerns (contaminants, incorrect dosing) are unknown and unstudied.
• Cost and access
  • Wegovy is often expensive and may have limited insurance coverage, though Novo Nordisk offers patient support/savings programs.
  • Compounded semaglutide can be substantially cheaper and easier to obtain through some clinics or pharmacies — that’s the main reason people choose it — but the tradeoff is the regulatory and quality uncertainty.

When people choose compounded semaglutide

• Cost savings or lack of access to Wegovy
• Need for nonstandard dosing or formulations (rare, patient‑specific) But those reasons should be balanced against the safety, legal and monitoring tradeoffs.

Safety/practical checklist if you’re considering compounded semaglutide

• Ask where the API came from and for a Certificate of Analysis (CoA).
• Use only a reputable compounding source: preferably an FDA‑registered 503B outsourcing facility or a pharmacy accredited by a recognized body (PCAB or ACHC) that follows USP sterile compounding standards.
• Ask if the pharmacy tests each batch for potency and sterility and what their expiry and storage instructions are.
• Avoid buying injections from unverified online sellers or social media. Those have led to contamination and counterfeit‑drug warnings from the FDA.
• Make sure dosing instructions are unambiguous and get training on injections if not using a pen device.
• Know that your insurance is unlikely to cover compounded versions.

Recommendations (specific names/services)

• For proven, regulated therapy: Wegovy (Novo Nordisk). Explanation: FDA‑approved for chronic weight management with standardized pens, known dosing/titration, and clinical-trial evidence.
• For price comparisons and savings programs: GoodRx and the Novo Nordisk Wegovy savings/support program. Explanation: GoodRx can show retail prices and coupons; Novo Nordisk offers patient assistance or co-pay programs that sometimes reduce out‑of‑pocket cost for Wegovy.
• If you consider compounding despite the risks: insist on a compounding vendor that is an FDA‑registered 503B outsourcing facility or is accredited (PCAB/ACHC) and can provide batch CoAs and sterile‑compounding documentation. (I can’t safely recommend a single compounding pharmacy here because quality varies by location — instead, ask your prescriber to source one meeting those standards.)

Bottom line If you want the assurance of FDA‑reviewed quality, known efficacy/safety and manufacturer support, Wegovy is the safer choice. Compounded semaglutide may be cheaper or more available, but it carries real risks from variable potency, sterility and untested formulations — so only consider it if you can verify the pharmacy’s sterile compounding credentials and testing, and you accept the tradeoffs.

If you want, tell me whether you’re being offered a compounded product (and by which pharmacy), and I’ll suggest specific questions to ask and what paperwork to request.